New! View global litigation for patent families

US20020164631A1 - Methods for stool sample preparation - Google Patents

Methods for stool sample preparation Download PDF

Info

Publication number
US20020164631A1
US20020164631A1 US10105877 US10587702A US2002164631A1 US 20020164631 A1 US20020164631 A1 US 20020164631A1 US 10105877 US10105877 US 10105877 US 10587702 A US10587702 A US 10587702A US 2002164631 A1 US2002164631 A1 US 2002164631A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
dna
sample
stool
methods
method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10105877
Inventor
Anthony Shuber
Stanley Lapidus
Gail Radcliffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shuber Anthony P
Original Assignee
Shuber Anthony P.
Lapidus Stanley N.
Radcliffe Gail E.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for mutation or polymorphism detection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6802General aspects
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for PCR assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Abstract

The present invention provides methods for the preparation of stool samples to increase the yield of relevant DNA, and further provides methods for isolating and analyzing target DNA for characteristics indicative of colorectal cancer. Methods for screening patients for the presence of cancerous or pre-cancerous colorectal lesions are also provided.

Description

    RELATED APPLICATIONS
  • [0001]
    This application is a continuation-in-part of U.S. application Ser. No. 08/876,638, filed Jun. 15, 1997.
  • FIELD OF THE INVENTION
  • [0002]
    This invention relates to methods for the early detection of colon cancer in patients, and more particularly to methods for preparing stool samples in order to increase the yield of nucleic acids.
  • BACKGROUND OF THE INVENTION
  • [0003]
    Stool samples frequently must be prepared for medical diagnostic analysis. Stool samples may be analyzed for diagnosis of medical conditions ranging from parasitic, bacterial or viral infections to inflammatory bowel disease and colorectal cancer.
  • [0004]
    Colorectal cancer is a leading cause of death in Western society. However, if diagnosed early, it may be treated effectively by removal of the cancerous tissue. Colorectal cancers originate in the colorectal epithelium and typically are not extensively vascularized (and therefore not invasive) during the early stages of development. Colorectal cancer is thought to result from the clonal expansion of a single mutant cell in the epithelial lining of the colon or rectum. The transition to a highly vascularized, invasive and ultimately metastatic cancer which spreads throughout the body commonly takes ten years or longer. If the cancer is detected prior to invasion, surgical removal of the cancerous tissue is an-effective cure. However,colorectal cancer is often detected only upon manifestation of clinical symptoms, such as pain and black tarry stool. Generally, such symptoms are present only when the disease is well established, and often after metastasis has occurred. Early detection of colorectal cancer therefore is important in order to significantly reduce its morbidity.
  • [0005]
    Invasive diagnostic methods such as endoscopic examination allow for direct visual identification, removal, and biopsy of potentially cancerous growths. Endoscopy is expensive, uncomfortable, inherently risky, and therefore not a practical tool for screening populations to identify those with colorectal cancer. Non-invasive analysis of stool samples for characteristics indicative of the presence of colorectal cancer or precancer is a preferred alternative for early diagnosis, but no known diagnostic method is available which reliably achieves this goal.
  • [0006]
    Current non-invasive screening methods involve assaying stool samples for the presence of fecal occult blood or for elevated levels of carcinoembryonic antigen, both of which are suggestive of the presence of colorectal cancer. Additionally, recent developments in molecular biology provide methods of great potential for detecting the presence of a range of DNA mutations or alterations indicative of colorectal cancer. The presence of such mutations can be detected in DNA found in stool samples during various stages of colorectal cancer. However, stool comprises cells and cellular debris from the patient, from microorganisms, and from food, resulting in a heterogeneous population of cells. This makes detection of small, specific subpopulations difficult to detect reliably.
  • [0007]
    Use of the polymarase chain reaction (PCR) has made detection of nucleic acids more routine, but any PCR is limited by the amount of DNA present in a sample. A minimum amount of material must be present for specific analysis and this limitation becomes more relevant when one seeks to detect a nucleic acid that is present in a sample in small proportion relative to other nucleic acids in the sample, which is often the case when analyzing stool sample for detecting DNA characteristics of colorectal cancer. If a low-frequency mutant strand is not amplified in the first few rounds of PCR, any signal obtained from the mutant strand in later rounds will be obscured by background or by competing signal from amplification of ubiquitous wild-type strand.
  • [0008]
    An additional problem encounter in preparation of stool sample for detection of colorectal cancer is the difficulty of extracting sufficient quantities of relevant DNA from the stool. Stool samples routinely contain cell debris, enzymes, bacteria (and associated nucleic acids), and various other compounds that can interfere with traditional DNA extraction procedures and reduce DNA yield. Furthermore, DNA in stool often appears digested or partially digested, which can reduce the efficiency of extraction methods.
  • SUMMARY OF THE INVENTION
  • [0009]
    It has now been appreciated that the yield of nucleic acid from a stool sample is increased by providing an optimal ratio of solvent volume to stool mass in the sample. Accordingly, the invention provides stool sample preparation protocols for increasing sample nucleic acid yield.
  • [0010]
    In a preferred embodiment, methods of the invention comprise homogenizing a representative stool sample in a solvent in order to form a homogenized sample mixture having a solvent volume to stool mass ratio of at least 5:1, then enriching the homogenized sample for the target (human) DNA. The human DNA may then be analyzed for the characteristics of disease. Providing an optimal solvent volume to stool mass ratio increases the yield of nucleic acid obtained from the sample. An especially-preferred ratio of solvent volume to stool mass is between about 10:1 and about 30:1, more preferably from about 10:1 to about 20:1, and most preferably 10:1.
  • [0011]
    A preferred solvent for preparing stool samples according to the invention is a physiologically-compatible buffer such as a buffer comprising Tris-EDTA-NaCl. A preferred buffer is a Tris-EDTA-NaCl buffer comprising about 50 to about 100 mM Tris, about 10 to about 20 mM EDTA, and about 5 to about 15 mM NaCl at about pH 9.0. A particularly preferred buffer is 50 mM Tris, 16 mM EDTA and 10 mM NaCl at pH 9.0. Another preferred solvent is guanidine isothiocyanate (GITC). A preferred GITC buffer has a concentration of about 1 M to about 5 M. A particularly preferred GITC buffer has a concentration of about 3 M.
  • [0012]
    Also in a preferred embodiment, methods further comprise the step of enriching the homogenized sample mixture for human DNA by, for example, using sequence-specific nucleic acid probes hybridizing to target human DNA.
  • [0013]
    In an alternative preferred embodiment, the methods of the invention comprise homogenizing a, stool sample in a physiologically-acceptable solvent for DNA in order to form a homogenized sample mixture having a solvent volume to stool mass ratio of at least 5:1; ensuring that the homogenized sample has at least a minimum number N of total DNA molecules to facilitate detection of a low-frequency target DNA molecule; and analyzing the target DNA for the characteristics of disease, preferably by amplifying the target DNA with a polymerase chain reaction.
  • [0014]
    In another embodiment, the present invention provides methods for analyzing DNA extracted from stool which comprise homogenizing a stool sample in a solvent for DNA in order to form a homogenized sample mixture having a solvent volume to stool mass ratio of at least 5:1; enriching the homogenized sample for human DNA; ensuring that the enriched homogenized sample has at least a minimum number N of total DNA molecules to provide for detection of a low-frequency target DNA molecule; and analyzing the target DNA for DNA characteristics indicative of disease.
  • [0015]
    Methods of the invention are useful to screen for the presence in a stool sample of nucleic acids indicative of colorectal cancer. Such methods comprise obtaining a representative stool sample (i.e., at least a cross-section); homogenizing the sample in a solvent having a solvent volume to stool mass ratio of at least 5:1; enriching the sample for target human DNA; and analyzing the DNA for characteristics of colorectal cancer. Various methods of analysis of DNA characteristics exist, such as those disclosed in co-owned, copending U.S. patent application Ser. No. 08/700,583, incorporated by reference herein.
  • [0016]
    Methods of the invention also comprise obtaining a representative (i.e., cross-sectional) sample of stool and homogenizing the stool in a buffer, such as a buffer comprising a detergent and a proteinase and optionally a DNase inhibitor.
  • [0017]
    The methods of the invention are especially and most preferably useful for detecting DNA characteristics indicative of a subpopulation of transformed cells in a representative stool sample. The DNA characteristics may be, for example, mutations, including point mutations, deletions, additions, translocations, substitutions, and loss of heterozygosity. Methods of the invention may further comprise a visual examination of the colon. Finally, surgical resection of abnormal tissue may be done in order to prevent the spread of cancerous or precancerous tissue.
  • [0018]
    Accordingly, methods of the invention provide means for screening for the presence of a cancerous or precancerous subpopulation of cells in a heterogeneous sample, such as a stool sample. Methods of the invention reduce morbidity and mortality associated with lesions of the colonic epithelium. Moreover, methods of the invention comprise more accurate and convenient screening methods than are currently available in the art, because such methods take advantage of the increased yield of relevant DNA.
  • [0019]
    Methods of the invention thus provide unexpected and enhanced detection and analysis of low-frequency DNA in a heterogeneous sample is facilitated through application of the methods described herein. That is, homogenization of stool sample in solvent at a ratio of at least 5:1 (volume to mass) alone, or in combination with methods for sample enrichment disclosed herein, provides a reliable method for obtaining a sufficient number of DNA molecules for effective and efficient analysis, even if the target molecule is a low-frequency DNA molecule. Further aspects and advantages of the invention are contained in the following detailed description thereof.
  • DESCRIPTION OF THE DRAWINGS
  • [0020]
    [0020]FIG. 1 is a representation of a partial nucleotide sequence of the kras gene (base pairs 62826571) and the positions of capture probe CP1, PCR primer A1, and PCR primer B1, in relation to the kras nucleotide sequence.
  • [0021]
    [0021]FIG. 2 is an image produced using a Stratagene Eagle Eye II Still Video System (Stratagene, La Jolla, Calif.), of the results of a gel electrophoresis run with the uncut DNA extracted as described in Example 2.
  • [0022]
    [0022]FIG. 3 is an image produced using a Stratagene Eagle Eye II Still Video System (Stratagene, La Jolla, Calif.), of the results of a gel electrophoresis run with the DNA extracted as described in Example 3.
  • DETAILED DESCRIPTION OF THE INVENTION
  • [0023]
    The invention provides improved methods for extraction and analysis of nucleic acids from stool. According to methods of the invention, the yield of nucleic acids extracted from stool is increased by homogenizing the stool in a buffer at optimal ratio of buffer volume to stool mass. Yield is further improved by enriching for human DNA. Improved nucleic acid yields allow nucleic acid analysis of stool samples to be conducted more efficiently with less stool volume.
  • [0024]
    In preferred methods of the invention a stool sample obtained for analysis comprises at least a cross-section of a whole stool. As provided in U.S. Pat. No. 5,741,650, incorporated by reference herein, cells and cellular debris from the colonic epithelium is deposited onto and into stool in a longitudinal streak. Obtaining at least a cross-section of a stool ensures that a representative sampling of colonic epithelial cells and cellular debris is analyzed.
  • [0025]
    Once the stool sample is collected, it is homogenized in a physiologically acceptable solvent. A preferred means of homogenization employs agitation with glass beads. Physiologically acceptable solvents include those solvents generally known to those skilled in the art as suitable for dispersion of biological sample material. Such solvents include phosphate-buffered saline comprising a salt, such as 20-100 mM NaCl or KCl, and optionally a detergent, such as 1-10% SDS or Triton™, and/or a proteinase, such as proteinase K (at, e.g., about 20 mg/ml). A preferred solvent is a physiologically-compatible buffer comprising, for example, 1 M Tris, 0.5M EDTA, 5M NaCl and water to a final concentration of 500 mM Tris, 16 mM EDTA and 10 mM NaCl at pH 9. The buffer acts as a solvent to disperse the solid stool sample during homogenization. Applicants have discovered that increasing the-volume of solvent in relation to solid mass of the sample results in increased yields of DNA.
  • [0026]
    According to methods of the invention, solvent (buffer) is added to the solid sample in a solvent volume to solid mass ratio of at least about 5:1. The solvent volume to solid mass ratio is preferably in the range of about 10:1 to about 30:1, and more preferably in the range of about 10:1 to about 20:1. Most preferably, the solvent volume to solid mass ratio is about 10:1. Typically, solvent volume may be measured in milliliters, and solid mass measured in milligrams, but the practitioner will appreciate that the ratio of volume to mass remains constant, regardless of scale up or down of the particular mass and volume units. That is, solvent volume to solid mass ratios may be measured as liters:grams or μl: μg.
  • [0027]
    In a preferred embodiment of the present invention, the homogenized sample is enriched for the target (human) DNA. In the context of the present invention, “enrichment” of the sample means manipulating the sample to decrease the amount of undesired, non-human DNA in the sample relative to the amount of target human DNA. Enrichment techniques include sequence-specific capture of target DNA or removal of bacterial nucleic acids.
  • [0028]
    In a preferred embodiment of the invention, the enrichment step is carried out in a physiologically compatible buffer, such as guanidine isothiocyanate (GITC). Capture probes are then added to the mixture to hybridize to target DNA in order to facilitate selective removal of target DNA from the sample.
  • [0029]
    Sequence specific capture of target DNA can be accomplished by initially denaturing sample DNA to form single-stranded DNA. Then, a sufficient quantity of sequence specific oligonucleotide probe that is complementary to at least a portion of a target polynucleotide (e.g., a sequence in or near the p53 allele) is added. The probe sequence (labeled with biotin) is allowed to hybridize to the complementary target DNA sequence. Beads coated with avidin or streptavidin are then added and attach to the biotinylated hybrids by affinity-binding. The beads may be magnetized to facilitate isolation.
  • [0030]
    After separation of probe-target hybrids, the resultant DNA is washed repeatedly to remove inhibitors, including those commonly introduced via the capture probe technique. In the methods of the present invention, washes are preferably carried out approximately four times with 1M GITC and 0.1% detergent, such as Igepal (Sigma). The initial washes are then preferably followed by two washes with a standard wash buffer (such as Tris-EDTA-NaCl) to remove the GITC from the mix, since GITC is a known inhibitor of DNA polymerases, including those associated with PCR.
  • [0031]
    Finally, the target DNA is eluted into a small volume of distilled water by heating. Assays using polymerase chain reaction (PCR), restriction fragment length polymorphism (RFLP) analysis or other nucleic acid analysis methods may be used to detect DNA characteristics indicative of a disorder, such as colorectal cancer or pre-cancer. Several particularly useful analytical techniques are described in co-pending U.S. applications Ser. Nos. 08/700,583, 08/815,576 and 08/877,333, the disclosures of which are incorporated herein by reference.
  • [0032]
    In an alternative embodiment, the homogenized sample is examined to determine that the sample has at least a minimum number (N) of total DNA molecules to provide for detection of a low-frequency target DNA molecule. The number of molecules analyzed in a sample determines the ability of the analysis to detect low-frequency events. In the case of PCR, the number of input molecules must be about 500 if the PCR efficiency is close to 100%. As PCR efficiency goes down, the required number of input molecules goes up. Analyzing the minimum number of input molecules reduces the probability that a low-frequency event is not detected in PCR because it is not amplified in the first few rounds. Methods of the invention therefore include determining a threshold number of sample molecules that must be analyzed in order to detect a low-frequency molecular event at a prescribed level of confidence.
  • [0033]
    As is more fully described in copending U.S. application Ser. No. ______ [Atty Docket No. EXT-021], which is incorporated herein by reference, the determination of a minimum number N of DNA molecules that must be present in a sample to permit amplification and analysis of a low-frequency target DNA molecule is based upon a model of stochastic processes in PCR. Utilizing pre-set or predetermined values for PCR efficiency and mutant DNA to wild-type DNA ratio in the sample, the model predicts the number of molecules that must be presented to the PCR in order to ensure, within a defined level of statistical confidence, that a low-frequency molecule will be amplified.
  • [0034]
    The skilled practitioner will appreciate that determination of the minimum number N of molecules present in the sample may be used in lieu of, or in addition to, the enrichment techniques detailed above, to ensure reliable results in the methods of the present invention.
  • [0035]
    Alternatively, methods of the invention may also be used to isolate total DNA from stool homogenate. The homogenized mixture is centrifuged to form a pellet made up of cell debris and stool matter, and a supernatant containing nucleic acid and associated proteins, lipids, etc. The supernatant is treated with a detergent, such as 20% SDS, and enzymes capable of degrading protein (e.g., Proteinase K). The supernatant is then Phenol-Chloroform extracted. The resulting purified nucleic acids are then precipitated by means known in the art. A variety of techniques in the art can then be employed to manipulate the resulting nucleic acids, including further purification or isolation of specific nucleic acids.
  • [0036]
    Methods of the invention are also useful for analysis of pooled DNA samples. As described in more detail in U.S. application Ser. No. 09/098,180, and U.S. Pat. No. 5,670,325, both of which are incorporated by reference herein, enumerative analysis of pooled genomic DNA samples is used to determine the presence or likelihood of disease. Pooled genomic DNA from healthy members of a population and pooled genomic DNA from diseased members of a population are obtained. The number or amount of each variant at a single-nucleotide polymorphic site is determined in each sample. The numbers or amounts are analyzed to determine if there is a statistically-significant difference between the variant(s) present in the sample obtained from the healthy population and those present in the sample obtained from the diseased population. A statistically-significant difference indicates that the polymorphic locus is a marker for disease.
  • [0037]
    These methods may be used to identify a nucleic acid (e.g., a polymorphic variant) associated with a disease. Such methods comprise counting the number or determining the amount of a nucleic acid, preferably a single base, in members of a diseased population, and counting numbers or determining amounts of the same nucleic acid in members of a healthy population. A statistically-significant difference in the numbers of the nucleic acid between the two populations is indicative that the interrogated locus is associated with a disease.
  • [0038]
    Once the polymorphic locus is identified, either by methods of the invention or by consulting an appropriate database, such methods are useful to determine which variant at the polymorphic locus is associated with a disease. In this case, enumerative methods are used to determine whether there is a statistically-significant difference between the number of a fist variant in members of a diseased population, and the number of a second variant at the same locus in members of a healthy population. A statistically-significant difference is indicative that the variant in members of the diseased population is useful as a marker for disease. Using this information, patients are screened for the presence of the variant that is thought to be associated with disease, the presence such a variant being indicative of the presence of disease, or a predisposition for a disease.
  • [0039]
    Methods of the present invention are particularly useful for isolation and analysis of nucleic acids that encompass genes that have mutations implicated in colorectal cancer, such as kras. The kras gene has a length of more than 30 kbp and codes for a 189 amino acid protein characterized as a low-molecular weight GTP-binding protein. The gene acquires malignant properties by single point mutations, the most common of which occurs at the 12th amino acid. Several studies have confirmed that approximately 40% of primary colorectal adenocarcinoma cells in humans contain a mutated form of the kras gene. Accordingly, the kras gene is a particularly suitable target for the methods of colorectal cancer detection of the present invention.
  • [0040]
    Toward this end, applicants have constructed a suitable exemplary capture probe directed to the kras nucleotide sequence. The capture probe, designated CP1, has the following sequence: 5′ GCC TGC TGA AM TGA CTG AAT ATA AAC TTG TGG TAG T 3′ (SEQ, ID NO: 1), and is preferably biotinylated at the 5′ end in order to facilitate isolation. As illustrated more fully below, CP1 is effective in the sequence specific capture of kras DNA.
  • [0041]
    Suitable PCR primers for the analysis of extracted kras DNA sequence have also been determined. Primer A1 has the sequence: 5° C. CTG CTG AAA ATG ACT GAA 3′ (SEQ ID NO: 2), and Primer B1 has the sequence: 5° CAT GM MT GGT CAG AGA M 3′ (SEQ ID NO: 3). The PCR primers A1 and B1, as well as capture probe CP1, are depicted in FIG. 1, showing their relation to the kras nucleotide sequence, base pairs 6282-6571 (SEQ ID NO: 4). One skilled in the art can construct other suitable capture probes and PCR primers for kras or other target genes or nucleotide sequences, using techniques well known in the art.
  • [0042]
    Accordingly, the methods of the present invention, which involve homogenizing stool sample in a volume of solvent such that the ratio of solvent volume to stool mass is at least 5:1, and/or enriching the sample for human DNA, provide a means for obtaining a sample having a minimum number N of total DNA molecules to facilitate detection of a low-frequency target DNA molecule. These methods thus provide the unexpected result that one is now able to reliably detect a small portion of low-frequency DNA in a heterogeneous sample.
  • [0043]
    The following examples provide further details of methods according to the invention. However, numerous additional aspects of the invention will become apparent upon consideration of the following examples.
  • EXAMPLE 1
  • [0044]
    Stool Sample Preparation
  • [0045]
    Voided stool was collected from a patient and a cross-sectional portion of the stool was removed for use as a sample. After determining the mass of the sample, an approximately 10×volume of Tris-EDTA-NaCl lysis buffer was added to the solid sample in a test tube. The final concentration of the buffer was 500 mM Tris, 16 mM EDTA and 10 mM NaCl, at a pH of about 9.0. Four 10 mm glass balls were placed in the tube and the tube and contents were homogenized in an Exactor II shaker for 15 minutes. The homogenized mixture was then allowed to stand 5 minutes at room temperature. The tube was then centrifuged for 5 minutes at 10,000 rpm in a Sorvall Centrifuge, and the supernatant was transferred to a clean test tube. A 20% SDS solution was added to the tube to a final concentration of 0.5%. Proteinase K was also added to the tube to a final concentration of 500 mg/ml. The tube was then incubated overnight at 37° C.
  • [0046]
    After incubation, the contents of the tube were extracted with an equal volume of phenol/chloroform and centrifuged at 3500 rpm for 3 minutes. The aqueous layer was then transferred to a new tube and extracted three (3) times with equal volumes of chloroform and centrifuged at 3500 rpm for 3 minutes. The aqueous layer was then transferred to a new tube and 0.1×volume of 3M NaOAc was added to the aqueous portion, which was then extracted with an equal volume of isopropanol, and centrifuged for 5 minutes at 12,000 rpm. The supernatant was discarded, and the pellet was washed with 10 ml of 70% ethanol, and centrifuged at 12,000 rpm for 5 minutes. The supernatant was discarded and the pellet containing isolated DNA was dried by inverting the tube.
  • EXAMPLE 2
  • [0047]
    A comparative analysis of solvent volume to mass ratios was conducted. Three separate stool samples were prepared as described above. A first sample, designated SS88-3×, was homogenized in buffer at a volume to mass ratio of 3:1. A second sample, designated SS88-5×, was homogenized at a ratio of 5:1; and a third sample, designated SS88-10×, was homogenized at a ratio of 10:1.
  • [0048]
    Total DNA from each sample was resuspended in 100 ul of 100 mM Tris, 10 mM EDTA buffer and 10 ul aliquots were loaded onto a 4% agarose gel for electrophoresis at 125 V constant voltage for about one hour. The results are shown in FIG. 2. As shown in FIG. 2, the yield of total DNA increased as the ratio of solvent to mass increased from 3×to 10×.
  • EXAMPLE 3
  • [0049]
    A second set of four equivalent samples was prepared from a single stool sample. Each of the four samples was of equal mass, and was homogenized as described in Example 1 at a solvent volume to stool mass ratio of 5:1, 10:1, 20:1, and 30:1, respectively. After homogenization each sample was subdivided into 8 aliquots, 4 treated with RNase, and 4 untreated. Total DNA was then isolated as described above and analyzed on agarose gels.
  • [0050]
    The results are shown in FIG. 3. As shown, a ratio of 10:1 produced the greatest yield of nucleic acids. FIG. 3 also shows the effect of RNase treatment on the yield of DNA from each stool sample. As shown in the Figure, RNase treatment virtually eliminates RNA from the sample, but leaves DNA intact. The results indicate that optimal solvent volume to stool mass ratios greatly increase DNA yield from stool samples.
  • EXAMPLE 4
  • [0051]
    Sequence-Specific Capture of Target DNA.
  • [0052]
    Once extracted from stool, specific nucleic acids are isolated using sequence-specific capture probes. Total DNA was extracted from a stool sample according to the methods described in Example 1. The pelletized DNA was resuspended in 1 ml of TE buffer. A 100 μl aliquot of this solution was removed to a new tube and 100 μl of 6M guanidine isothiocyanate (GITC) was added to a final concentration of 3M GITC. A vast excess of biotinylated kras capture probe CP1 was the added to the sample. The mixture was heated to 95° C. for 5 minutes to denature the DNA, then cooled to 37° C. for 5 minutes. Finally, probe and target DNA were allowed to hybridize for 30 minutes at room temperature. Streptavidin-coated magnetized beads (320 mg) (Dynal Corp.) were suspended in 400 μl distilled water and added to the mixture. After briefly mixing, the tube was maintained at room temperature for 30 minutes.
  • [0053]
    Once the affinity binding was completed, a magnetic field was applied to the sample to draw the magnetized isolation beads (both with and without hybridized complex out of the sample. The beads were then washed four (4) times in 1M GITC/0.1% Igepal (Sigma, St. Louis, Mo.) solution for 15 minutes, followed by two (2) washes with wash buffer (TE with 1M NaCl) for 15 minutes in order to isolate complexed streptavidin. Finally, 10 μl distilled water was added to the beads and heated at 95° C. for 3 minutes to elute the DNA. Sequencing and/or gel electrophoresis enable confirmation of the capture of kras-specific DNA.
  • [0054]
    Accordingly, methods of the invention produce increased yields of DNA from stool, thereby allowing more efficient sequence-specific capture of target nucleic acid. Methods of the invention provide improvements in the ability to detect disease-related nucleic acid mutations present in stool. The skilled artisan will find additional applications and embodiments of the invention useful upon inspection of the foregoing description of the invention. Therefore, the invention is limited only by the scope of the appended claims.
  • 1 4 1 37 DNA Artificial Sequence misc_feature Description of Artificial Sequence CP1 kras capture probe 1 gcctgctgaa aatgactgaa tataaacttg tggtagt 37 2 19 DNA Artificial Sequence misc_feature Description of Artificial Sequence kras PCR Primer A1 2 cctgctgaaa atgactgaa 19 3 20 DNA Artificial Sequence misc_feature Description of Artificial Sequence kras PCR primer B1 3 catgaaaatg gtcagagaaa 20 4 307 DNA homo sapiens misc_feature Partial nucleotide sequence of the kras gene 4 gtactggtgg agtatttgat agtgtattaa ccttatgtgt gacatgttct aatatagtca 60 cattttcatt atttttatta taaggcctgc tgaaaatgac tgaatataaa cttgtggtag 120 ttggagctgg tggcgtaggc aagagtgcct tgacgataca gctaattcag aatcattttg 180 tggacgaata tgatccaaca atagaggtaa atcttgtttt aatatgcata ttactggtgc 240 aggaccattc tttgatacag ataaaggttt ctctgaccat tttcatgtac agaagtcctt 300 gctaaga 307

Claims (40)

    What is claimed is:
  1. 1. A method for analyzing DNA extracted from stool, comprising:
    homogenizing a stool sample in a solvent for DNA in order to form a homogenized sample mixture having a solvent volume to stool mass ratio of at least 5:1;
    enriching said homogenized sample for human DNA; and
    analyzing said human DNA for characteristics of disease.
  2. 2. The method of claim 1 wherein the solvent volume to stool mass ratio is from about 10:1 to about 30:1.
  3. 3. The method of claim 2 wherein the solvent volume to stool mass ratio is about 10:1 to about 20:1.
  4. 4. The method of claim 2 wherein the solvent volume to stool mass ratio is about 10:1.
  5. 5. The method of claim 1 wherein the solvent comprises a physiologically compatible buffer.
  6. 6. The method of claim 5 wherein the buffer comprises Tris-EDTA-NaCl.
  7. 7. The method of claim 6 wherein the Tris-EDTA-NaCl buffer comprises a final concentration of about 50 mM Tris, about 16 mM EDTA and about 10 mM NaCl at about pH 9.0.
  8. 8. The method of claim 1 wherein the solvent comprises guanidine isothiocyanate buffer.
  9. 9. The method of claim 8 wherein the guanidine isothiocyanate buffer comprises a final concentration of from about 1 to about 5 M.
  10. 10. The method of claim 9 wherein the guanidine isothiocyanate buffer comprises a final concentration of about 3 M.
  11. 11. The method of claim 1 wherein said enriching step comprises contacting said DNA with a sequence-specific capture probe.
  12. 12. The method of claim 1 wherein said solvent comprises a detergent and a proteinase.
  13. 13. The method of claim 1 wherein said DNA is human DNA.
  14. 14. A method of screening for the presence of a colorectal cancerous or pre-cancerous lesion in a patient, the method comprising the steps of:
    obtaining a sample comprising at least a cross-sectional portion of a stool voided by the patient;
    homogenizing the sample in a solvent in order to form a homogenized sample mixture having a solvent volume to stool mass ratio of at least 5:1;
    enriching said sample for a target human DNA; and
    analyzing the target human DNA for DNA characteristics indicative of the presence of said colorectal cancerous or pre-cancerous lesion.
  15. 15. The method of claim 14 wherein said analyzing step comprises amplifying the DNA with a polymerase chain reaction.
  16. 16. The method of claim 14 wherein said DNA characteristics comprise a loss of heterozygosity encompassing a polymorphic locus.
  17. 17. The method of claim 14 wherein said DNA characteristic is a mutation.
  18. 18. The method of claim 17 wherein said mutation is selected from the group consisting of loss of heterozygosity and microsatellite instability.
  19. 19. The method of claim 14 wherein said DNA characteristics comprise a deletion in a tumor suppressor allele.
  20. 20. The method of claim 14 wherein said analyzing step comprises determining whether a difference exists in said sample between a number X of a first allele known or suspected to be mutated in a subpopulation of cells in the sample and a number Y of a second allele that is known or suspected not to be mutated in a subpopulation of cells in the sample, the presence of a statistically-significant difference being indicative of a mutation in a subpopulation of cells in the sample and the potential presence of a cancerous or precancerous lesion.
  21. 21. The method of claim 14 wherein said analyzing step comprises determining whether a difference exists between a number of a target tumor suppressor allele in the sample and a number of a non-cancer-associated reference allele in the sample, the presence of a statistically-significant difference being indicative of a deletion of the target tumor suppressor allele in a subpopulation of cells in the sample and the potential presence of a cancerous or precancerous lesion.
  22. 22. The method of claim 14 wherein said analyzing step further comprises the steps of:
    a) detecting an amount of a maternal allele at a polymorphic locus in the sample;
    b) detecting an amount of a paternal allele at the polymorphic locus in the sample; and
    c) determining whether a difference exists between the amounts of maternal and paternal allele,
    the presence of a statistically-significant difference being indicative of a deletion at the polymorphic locus in a subpopulation of cells in the sample and the potential presence of a lesion.
  23. 23. The method of claim 22 wherein said polymorphic locus is a single base polymorphism and is heterozygous between said maternal and paternal alleles.
  24. 24. The method of claim 22 wherein said detecting steps comprise,
    a) hybridizing probe to a portion of said polymorphic locus on both maternal and paternal alleles that is immediately adjacent to said single-base polymorphism;
    b) exposing said sample to a mixture of detectably-labeled dideoxy nucleoside triphosphates under conditions which allow appropriate binding of said dideoxy nucleoside triphosphates to said single-base polymorphism;
    c) washing the sample; and
    d) counting an amount of each detectably-labeled dideoxy nucleoside triphosphate remaining for the sample.
  25. 25. The method of claim 24 wherein said detectable label is selected from the group consisting of radioisotopes, fluorescent compounds, and particles.
  26. 26. The method of claim 14 wherein said analyzing step comprises a method for detecting heterozygosity at a single-nucleotide polymorphic locus, comprising the steps of.
    a) hybridizing probes to a sequence immediately adjacent to a single-base polymorphism;
    b) exposing the sample to a plurality of different labeled dideoxy nucleotides
    c) washing the sample;
    d) determining which of said dideoxy nucleotides are incorporated into said probes; and
    e) detecting heterozygosity at the single-nucleotide polymorphic site as the detection of two dideoxy nucleotides having been incorporated into the probe.
  27. 27. The method of claim 14 wherein said analyzing step comprises:
    (a) exposing the sample to a plurality of a first oligonucleotide probe and to a plurality of a second oligonucleotide probe under hybridization conditions, thereby to hybridize
    (1) said first oligonucleotide probes to copies of a first polynucleotide segment characteristic of wild-type cells of the organism, and
    (2) said second oligonucleotide probes to copies of a second polynucleotide segment characteristic of a wild-type genomic region suspected to be deleted or mutated in colorectal cancer cells;
    (b) detecting a first number of duplexes formed between said first probe and said first segment and a second number of duplexes formed between said second probe and said second segment; and
    (c) determining whether there is a difference between the number of duplexes formed between said first probe and said first segment and the number of duplexes formed between said second probe and said second segment,
    the presence of a statistically-significant difference being indicative of the presence in said sample of a colorectal cancer or precancerous lesion.
  28. 28. The method of claim 27 wherein said first and second oligonucleotide probes each are coupled to a distinct detectable label.
  29. 29. The method of claim 27 wherein
    said first oligonucleotide probes are attached to a first particle in a ratio of one first oligonucleotide probe to one particle and said second oligonucleotide probes are attached to a second particle detectably distinct from said first particle in a ratio of one second oligonucleotide probe to one second particle, wherein
    said detecting step comprises separating hybridized from unhybridized first and second oligonucleotide probes and subsequently passing hybridized first and second oligonucleotide probes through a detector to determine said first and second numbers.
  30. 30. The method of claim 29 wherein said first and second particles are of detectably different sizes.
  31. 31. The method of claim 29 wherein said first and second particles are of detectably different colors.
  32. 32. The method of claim 27 further comprising, prior to step a) the steps of converting double-stranded DNA in said sample to single-stranded DNA and removing complement to said first and second polynucleotide segments.
  33. 33. The method of claim 32 wherein said removing step comprises hybridizing said complement to a nucleic acid probe attached to a magnetic particle and subsequently removing said magnetic particle from the sample.
  34. 34. The method of claim 14 wherein said analyzing step comprises a method for detecting a nucleic acid sequence change in a target allele in the sample, comprising the steps of:
    (a) determining
    (i) an amount of wild-type target allele in the sample, and
    (ii) an amount of a reference allele in the sample; and
    (b) detecting a nucleic acid sequence change in the target allele in the sample,
    a statistically significant difference in the amount wild-type target allele and the amount of reference allele obtained in said determining step being indicative of a nucleic acid sequence change.
  35. 35. The method according to claim 34 wherein said determining step comprises exposing said sample to a first oligonucleotide probe capable of hybridizing with a portion of said wild-type allele and to a second oligonucleotide probe capable of hybridizing to a portion of said reference allele, and removing from said sample any unhybridized first or second oligonucleotide probe.
  36. 36. A method for screening for the presence of a colorectal cancerous or precancerous lesion in a patient, the method comprising the steps of:
    obtaining a sample comprising at least a cross-sectional portion of a stool voided by the patient;
    homogenizing the sample in a solvent in order to form a homogenized sample mixture having a solvent volume to stool mass ratio of at least 5:1;
    ensuring that said sample have at least a minimum number N of total DNA molecules to provide for detection of a low-frequency target DNA molecule;
    analyzing the target DNA for DNA characteristics indicative of the presence of said colorectal cancerous or pre-cancerous lesion.
  37. 37. A method for screening for the presence of a colorectal cancerous or precancerous lesion in a patient, the method comprising the steps of:
    obtaining a sample containing of least a cross-sectional portion of a stool voided by the patient;
    homogenizing the sample in a solvent in order to form a homogenized sample mixture having a solvent volume to stool mass ratio of at least 5:1;
    enriching said homogenized sample for target human DNA;
    ensuring that said sample have at least a minimum number N of total DNA molecules to provide for detection of a low-frequency target DNA molecule;
    analyzing the target human DNA for DNA characteristics indicative of the presence of said colorectal cancerous or pre-cancerous lesion.
  38. 38. The method of claim 36 wherein said analyzing step comprises amplifying the DNA with a polymerase chain reaction.
  39. 39. The method of claim 37 wherein said analyzing step comprises amplifying the DNA with a polymerase chain reaction.
  40. 40. The method of claim 37 wherein said enriching step comprises contacting said DNA with a sequence-specific capture probe.
US10105877 1997-06-16 2002-03-25 Methods for stool sample preparation Abandoned US20020164631A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US87663897 true 1997-06-16 1997-06-16
US09198083 US6268136B1 (en) 1997-06-16 1998-11-23 Methods for stool sample preparation
US09862167 US6406857B1 (en) 1997-06-16 2001-05-21 Methods for stool sample preparation
US10105877 US20020164631A1 (en) 1997-06-16 2002-03-25 Methods for stool sample preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10105877 US20020164631A1 (en) 1997-06-16 2002-03-25 Methods for stool sample preparation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09862167 Continuation US6406857B1 (en) 1997-06-16 2001-05-21 Methods for stool sample preparation

Publications (1)

Publication Number Publication Date
US20020164631A1 true true US20020164631A1 (en) 2002-11-07

Family

ID=26893464

Family Applications (2)

Application Number Title Priority Date Filing Date
US09862167 Expired - Lifetime US6406857B1 (en) 1997-06-16 2001-05-21 Methods for stool sample preparation
US10105877 Abandoned US20020164631A1 (en) 1997-06-16 2002-03-25 Methods for stool sample preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09862167 Expired - Lifetime US6406857B1 (en) 1997-06-16 2001-05-21 Methods for stool sample preparation

Country Status (1)

Country Link
US (2) US6406857B1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087258A1 (en) * 1997-10-23 2003-05-08 Shuber Anthony P. Methods for detecting hypermethylated nucleic acid in heterogeneous biological samples
US6750020B2 (en) 2001-03-15 2004-06-15 Exact Sciences Corporation Method for alteration detection
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
US6911308B2 (en) 2001-01-05 2005-06-28 Exact Sciences Corporation Methods for detecting, grading or monitoring an H. pylori infection
US7776524B2 (en) 2002-02-15 2010-08-17 Genzyme Corporation Methods for analysis of molecular events
US7811757B2 (en) 1999-09-08 2010-10-12 Genzyme Corporation Methods for disease detection
US20100261221A1 (en) * 2007-07-26 2010-10-14 California Pacific Medical Center Method to predict or diagnose a gastrointestinal disorder or disease
US7981607B2 (en) 2004-08-27 2011-07-19 Esoterix Genetic Laboratories LLC Method for detecting recombinant event
US7981612B2 (en) 1999-12-07 2011-07-19 Mayo Foundation For Medical Education And Research Methods of screening for supracolonic neoplasms based on stool samples containing a nucleic acid marker indicative of a neoplasm
US20120288867A1 (en) * 2011-05-12 2012-11-15 Exact Sciences Corporation Serial isolation of multiple dna targets from stool
US20120288868A1 (en) * 2011-05-12 2012-11-15 Exact Sciences Corporation Isolation of nucleic acids
US8980107B2 (en) 2011-05-12 2015-03-17 Exact Sciences Corporation Spin filter
US8993341B2 (en) 2011-05-12 2015-03-31 Exact Sciences Corporation Removal of PCR inhibitors
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
US9777314B2 (en) 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1169479B1 (en) * 1999-04-09 2006-06-28 EXACT Sciences Corporation Methods for detecting nucleic acids indicative of cancer
US6849403B1 (en) 1999-09-08 2005-02-01 Exact Sciences Corporation Apparatus and method for drug screening
US6919174B1 (en) * 1999-12-07 2005-07-19 Exact Sciences Corporation Methods for disease detection
US7217542B2 (en) * 2002-10-31 2007-05-15 Hewlett-Packard Development Company, L.P. Microfluidic system for analyzing nucleic acids
US20040086895A1 (en) * 2002-11-06 2004-05-06 Crothers Donald M. Method of electrochemical detection of somatic cell mutations
JP4134047B2 (en) * 2003-03-19 2008-08-13 財団法人浜松科学技術研究振興会 Colon cancer marker detection method
US20040259101A1 (en) * 2003-06-20 2004-12-23 Shuber Anthony P. Methods for disease screening
WO2005111244A3 (en) * 2004-05-10 2006-06-22 Exact Sciences Corp Methods for detecting a mutant nucleic acid
US20080124714A1 (en) * 2004-05-14 2008-05-29 Exact Sciences Corporation Method for Stabilizing Biological Samples for Nucleic Acid Analysis
US20090042280A1 (en) * 2004-12-13 2009-02-12 Geneohm Sciences, Inc., Fluidic cartridges for electrochemical detection of dna
US20110045991A1 (en) * 2005-06-23 2011-02-24 Sadanand Gite Methods for the Detection of Colorectal Cancer
CA2618650A1 (en) * 2005-08-10 2007-02-15 Hamamatsu Foundation For Science And Technology Promotion Method for detecting colon cancer markers
GB201107466D0 (en) 2011-05-05 2011-06-15 Loktionov Alexandre Device and method for non-invasive collection of colorectal mucocellular layer and disease detection
US9222623B2 (en) 2013-03-15 2015-12-29 Genmark Diagnostics, Inc. Devices and methods for manipulating deformable fluid vessels
US9498778B2 (en) 2014-11-11 2016-11-22 Genmark Diagnostics, Inc. Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system
US9598722B2 (en) 2014-11-11 2017-03-21 Genmark Diagnostics, Inc. Cartridge for performing assays in a closed sample preparation and reaction system

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4101279A (en) 1977-04-06 1978-07-18 Muhammed Javed Aslam Device for the collection and processing of stool specimens
US4333734A (en) 1980-01-18 1982-06-08 Sloan-Kettering Institute For Cancer Research Diagnostic device for fecal occult blood and method of use
US4309782A (en) 1980-09-11 1982-01-12 Esteban Paulin Device for collecting fecal specimens
US4358535B1 (en) 1980-12-08 1986-05-13
US5482834A (en) 1982-05-17 1996-01-09 Hahnemann University Evaluation of nucleic acids in a biological sample hybridization in a solution of chaotrophic salt solubilized cells
US4445235A (en) 1982-09-13 1984-05-01 Pearl Slover Stool specimen collector
US4535058A (en) 1982-10-01 1985-08-13 Massachusetts Institute Of Technology Characterization of oncogenes and assays based thereon
US4578358A (en) 1983-05-03 1986-03-25 Warner-Lambert Company Collection of specimens and detection of occult blood therein
US4683202B1 (en) 1985-03-28 1990-11-27 Cetus Corp
US4871838A (en) 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
US4705050A (en) 1985-10-02 1987-11-10 Markham Charles W Moisture-activated floatation device
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
US5348855A (en) 1986-03-05 1994-09-20 Miles Inc. Assay for nucleic acid sequences in an unpurified sample
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US4981783A (en) 1986-04-16 1991-01-01 Montefiore Medical Center Method for detecting pathological conditions
CA1341576C (en) 1986-08-11 2008-07-08 Thaddeus P. Dryja Diagnosis of retinoblastoma
US4735905A (en) 1986-08-15 1988-04-05 V-Tech, Inc. Specimen-gathering apparatus and method
US4935342A (en) 1986-12-01 1990-06-19 Syngene, Inc. Method of isolating and purifying nucleic acids from biological samples
JPS6434291A (en) 1987-03-23 1989-02-03 Ici Plc Polynucleotide sequence, its production, polypeptide, fragment, antibody, polynucleotide specimen, diagnosis and estimation of malignant disease and examination of presence or absence of factor of malignant disease
US4857300A (en) 1987-07-27 1989-08-15 Cytocorp, Inc. Cytological and histological fixative formulation and methods for using same
JPH0221853A (en) 1988-04-15 1990-01-24 Montefiore Medical Center Method for confirmation of progression state of disease
FR2630000A1 (en) 1988-04-18 1989-10-20 Sultan Bernard Bottle indicated to collect a urine sample for biological examination cytobacteriological
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5248671A (en) 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5380645A (en) 1989-03-16 1995-01-10 The Johns Hopkins University Generalized method for assessment of colorectal carcinoma
US5527676A (en) 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
DE69032864T3 (en) 1989-03-29 2013-01-31 The Johns Hopkins University Detecting the failure of the wild-type p53 gene
US5196167A (en) 1989-04-04 1993-03-23 Helena Laboratories Corporation Fecal occult blood test product with positive and negative controls
US5192501A (en) 1989-04-04 1993-03-09 Helena Laboratories Corporation Method of formulating a test ink for a fecal occult blood test product
US5589335A (en) 1989-04-05 1996-12-31 Amoco Corporation Hybridization promotion reagents
DK0407789T3 (en) 1989-06-23 1993-11-01 Canon Kk A method for detecting nucleic acids
US5302509A (en) 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
CA2029219A1 (en) 1989-11-08 1991-05-09 Mary K. Estes Methods and reagents to detect and characterize norwalk and related viruses
US5641628A (en) 1989-11-13 1997-06-24 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal DNA
US5137806A (en) 1989-12-11 1992-08-11 Board Of Regents, The University Of Texas System Methods and compositions for the detection of sequences in selected DNA molecules
JPH05508307A (en) 1990-01-04 1993-11-25
US5126239A (en) 1990-03-14 1992-06-30 E. I. Du Pont De Nemours And Company Process for detecting polymorphisms on the basis of nucleotide differences
US5200314A (en) 1990-03-23 1993-04-06 Chiron Corporation Polynucleotide capture assay employing in vitro amplification
DK1013666T3 (en) 1990-06-27 2006-08-14 Univ Princeton The protein complexes of p53 / p90
JPH06510363A (en) 1990-10-29 1994-11-17
US5846710A (en) 1990-11-02 1998-12-08 St. Louis University Method for the detection of genetic diseases and gene sequence variations by single nucleotide primer extension
US5352775A (en) 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
DE69210588T2 (en) 1991-02-05 1996-09-19 Lifecodes Corp Molecular genetic identification using probes that detect polymorphic sites
CA2101943A1 (en) 1991-02-05 1992-08-06 Kamal Bahar Simple test for detecting carcinoembryonic antigen
US5330892A (en) 1991-03-13 1994-07-19 The Johns Hopkins University MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans
US5468610A (en) 1991-05-29 1995-11-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Three highly informative microsatellite repeat polymorphic DNA markers
US5378602A (en) 1991-05-29 1995-01-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Highly informative microsatellite repeat polymorphic DNA markers twenty-[seven]six
US5362623A (en) 1991-06-14 1994-11-08 The John Hopkins University Sequence specific DNA binding by p53
US5149506A (en) 1991-08-09 1992-09-22 Sage Products, Inc. Stool collection and transport device
US5506105A (en) 1991-12-10 1996-04-09 Dade International Inc. In situ assay of amplified intracellular mRNA targets
EP0672181B1 (en) 1992-04-01 2003-11-05 The Johns Hopkins University School Of Medicine Methods of detecting mammalian nucleic acids isolated from stool specimen and reagents therefor
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5409586A (en) 1992-08-26 1995-04-25 Hitachi, Ltd. Method for analyzing nucleic acid or protein and apparatus therefor
US5331973A (en) 1993-03-15 1994-07-26 Fiedler Paul N Method for obtaining stool samples for gastrointestinal cancer testing
CA2092115C (en) 1993-03-22 1998-12-15 Janet L. Taylor Testing for infestation of rapeseed and other cruciferae by the fungus leptosphaeria maculans (blackleg infestation)
US5492808A (en) 1993-05-05 1996-02-20 The Johns Hopkins University Means for detecting familial colon cancer (FCC)
US5466576A (en) 1993-07-02 1995-11-14 Fred Hutchinson Cancer Research Center Modulation of PIF-1-type helicases
DE69431510T2 (en) 1993-07-08 2003-02-27 Johnson & Johnson Clin Diag A process for the co-amplification of two different nucleic acid sequences using the polymerase chain reaction
CA2143428A1 (en) 1993-07-09 1995-01-19 Takanori Oka Method of nucleic acid-differentiation and assay kit for nucleic acid-differentiation
US5416025A (en) 1993-11-29 1995-05-16 Krepinsky; Jiri J. Screening test for early detection of colorectal cancer
US5681697A (en) 1993-12-08 1997-10-28 Chiron Corporation Solution phase nucleic acid sandwich assays having reduced background noise and kits therefor
US5709998A (en) 1993-12-15 1998-01-20 The Johns Hopkins University Molecular diagnosis of familial adenomatous polyposis
US5538851A (en) 1993-12-22 1996-07-23 Institut Pasteur And Cneva Primers for the amplification of genes coding for the enterotoxin and the lecithinase of Clostridium perfringens and their application to the determination of the presence and numeration of these bacteriae
US5496470A (en) 1994-05-27 1996-03-05 Barnes International, Inc. Magnetic separator
US6037465A (en) 1994-06-14 2000-03-14 Invitek Gmbh Universal process for isolating and purifying nucleic acids from extremely small amounts of highly contaminated various starting materials
US5512441A (en) 1994-11-15 1996-04-30 American Health Foundation Quantative method for early detection of mutant alleles and diagnostic kits for carrying out the method
US5463782A (en) 1994-11-21 1995-11-07 Eric V. Carlson Foldable stool sample collection device
DE19530132C2 (en) 1995-08-16 1998-07-16 Max Planck Gesellschaft A process for purifying, stabilizing or isolating nucleic acids from biological materials
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
US5741650A (en) 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US6143529A (en) 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US5670325A (en) 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US6020137A (en) 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US6100029A (en) 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6300077B1 (en) 1996-08-14 2001-10-09 Exact Sciences Corporation Methods for the detection of nucleic acids
US6146828A (en) 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US5856104A (en) 1996-10-28 1999-01-05 Affymetrix, Inc. Polymorphisms in the glucose-6 phosphate dehydrogenase locus
US5830665A (en) 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6268136B1 (en) 1997-06-16 2001-07-31 Exact Science Corporation Methods for stool sample preparation
US5888778A (en) 1997-06-16 1999-03-30 Exact Laboratories, Inc. High-throughput screening method for identification of genetic mutations or disease-causing microorganisms using segmented primers
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6503718B2 (en) 1999-01-10 2003-01-07 Exact Sciences Corporation Methods for detecting mutations using primer extension for detecting disease
US6280947B1 (en) 1999-08-11 2001-08-28 Exact Sciences Corporation Methods for detecting nucleotide insertion or deletion using primer extension

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818404B2 (en) 1997-10-23 2004-11-16 Exact Sciences Corporation Methods for detecting hypermethylated nucleic acid in heterogeneous biological samples
US20030087258A1 (en) * 1997-10-23 2003-05-08 Shuber Anthony P. Methods for detecting hypermethylated nucleic acid in heterogeneous biological samples
US7811757B2 (en) 1999-09-08 2010-10-12 Genzyme Corporation Methods for disease detection
US7981612B2 (en) 1999-12-07 2011-07-19 Mayo Foundation For Medical Education And Research Methods of screening for supracolonic neoplasms based on stool samples containing a nucleic acid marker indicative of a neoplasm
US6911308B2 (en) 2001-01-05 2005-06-28 Exact Sciences Corporation Methods for detecting, grading or monitoring an H. pylori infection
US6750020B2 (en) 2001-03-15 2004-06-15 Exact Sciences Corporation Method for alteration detection
US7776524B2 (en) 2002-02-15 2010-08-17 Genzyme Corporation Methods for analysis of molecular events
US8409829B2 (en) 2002-02-15 2013-04-02 Esoterix Genetic Laboratories, Llc Methods for analysis of molecular events
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
US20080206756A1 (en) * 2003-07-18 2008-08-28 California Pacific Medical Center Biomarker panel for colorectal cancer
US8389220B2 (en) 2004-08-27 2013-03-05 Esoterix Genetic Laboratories, Llc Method for detecting a recombinant event
US7981607B2 (en) 2004-08-27 2011-07-19 Esoterix Genetic Laboratories LLC Method for detecting recombinant event
US9109256B2 (en) 2004-10-27 2015-08-18 Esoterix Genetic Laboratories, Llc Method for monitoring disease progression or recurrence
US9777314B2 (en) 2005-04-21 2017-10-03 Esoterix Genetic Laboratories, Llc Analysis of heterogeneous nucleic acid samples
US9353420B2 (en) 2007-07-26 2016-05-31 Nancy M. Lee Method to predict or diagnose a gastointestinal disorder or disease
US20100261221A1 (en) * 2007-07-26 2010-10-14 California Pacific Medical Center Method to predict or diagnose a gastrointestinal disorder or disease
US8883440B2 (en) 2007-07-26 2014-11-11 Nancy M. Lee Method to predict or diagnose a gastrointestinal disorder or disease
US20150284770A1 (en) * 2011-05-11 2015-10-08 Exact Sciences Corporation Isolation of nucleic acids
US20140193813A1 (en) * 2011-05-11 2014-07-10 Exact Sciences Corporation Isolation of nucleic acids
US20140194607A1 (en) * 2011-05-11 2014-07-10 Exact Sciences Corporation Isolation of nucleic acids
US20140194608A1 (en) * 2011-05-11 2014-07-10 Exact Sciences Corporation Isolation of nucleic acids
US8808990B2 (en) * 2011-05-12 2014-08-19 Exact Sciences Corporation Serial isolation of multiple DNA targets from stool
US8980107B2 (en) 2011-05-12 2015-03-17 Exact Sciences Corporation Spin filter
CN104450680A (en) * 2011-05-12 2015-03-25 精密科学公司 Isolation of nucleic acids
US8993341B2 (en) 2011-05-12 2015-03-31 Exact Sciences Corporation Removal of PCR inhibitors
US9000146B2 (en) * 2011-05-12 2015-04-07 Exact Sciences Corporation Isolation of nucleic acids
US8999176B2 (en) 2011-05-12 2015-04-07 Exact Sciences Corporation Isolation of nucleic acids
US9057098B2 (en) * 2011-05-12 2015-06-16 Exact Sciences Corporation Isolation of nucleic acids
US20150010907A1 (en) * 2011-05-12 2015-01-08 Exact Sciences Corporation Serial isolation of multiple dna targets from stool
CN103649298A (en) * 2011-05-12 2014-03-19 精密科学公司 Isolation of nucleic acids
US9163278B2 (en) * 2011-05-12 2015-10-20 Exact Sciences Corporation Isolation of nucleic acids
US9169511B2 (en) * 2011-05-12 2015-10-27 Exact Sciences Corporation Isolation of nucleic acids
US20120288868A1 (en) * 2011-05-12 2012-11-15 Exact Sciences Corporation Isolation of nucleic acids
US9631228B2 (en) * 2011-05-12 2017-04-25 Exact Sciences Corporation Isolation of nucleic acids
US9657330B2 (en) * 2011-05-12 2017-05-23 Exact Sciences Corporation Serial isolation of multiple DNA targets from stool
US20120288867A1 (en) * 2011-05-12 2012-11-15 Exact Sciences Corporation Serial isolation of multiple dna targets from stool
US9845491B2 (en) 2011-05-12 2017-12-19 Exact Sciences Corporation Isolation of nucleic acids
US9856515B2 (en) 2011-05-12 2018-01-02 Exact Sciences Corporation Removal of PCR inhibitors

Also Published As

Publication number Publication date Type
US6406857B1 (en) 2002-06-18 grant

Similar Documents

Publication Publication Date Title
Marsh et al. Germline PTEN mutations in Cowden syndrome-like families.
Caldas et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia
US20040086944A1 (en) Detection of methylated dna molecules
US6939671B2 (en) Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
US6280947B1 (en) Methods for detecting nucleotide insertion or deletion using primer extension
US5650277A (en) Method of determining the presence and quantifying the number of di- and trinucleotide repeats
US20040248172A1 (en) Detection of clonal T-cell receptor-gamma gene rearrangement by PCR/temporal temperature gradient gel electrophoresis (TTGE)
US6428964B1 (en) Method for alteration detection
Anker et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer
US6143529A (en) Methods for improving sensitivity and specificity of screening assays
WO1995021944A1 (en) Differentially expressed genes in healthy and diseased subjects
US20080161420A1 (en) Method For Monitoring Disease Progression or Recurrence
Gad et al. Color bar coding the BRCA1 gene on combed DNA: a useful strategy for detecting large gene rearrangements
US6498012B2 (en) Methods for detecting mutations using primer extension for detecting disease
US6303304B1 (en) Methods for disease diagnosis from stool samples
WO1998049342A1 (en) Method of preparing a standard diagnostic gene transcript pattern
US6964846B1 (en) Methods for detecting nucleic acids indicative of cancer
WO1997007239A1 (en) Process for purifying, stabilising or isolating nucleic acids from biological materials
US7387874B2 (en) Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assay
WO2004044209A1 (en) A method of detection
WO2000053802A1 (en) Compositions and methods for genetic analysis
US20080145852A1 (en) Methods and compositions for detecting adenoma
WO1994001447A1 (en) Methods of single nucleotide primer extension to detect specific alleles and kits therefor
US6632610B2 (en) Methods of identification and isolation of polynucleotides containing nucleic acid differences
US20070087358A1 (en) Methods for diagnosing cancer based on DNA methylation status in NBL2